136 related articles for article (PubMed ID: 17513824)
1. Temporal dependence of the effect of radiation on erlotinib-induced skin rash.
Lacouture ME; Hwang C; Marymont MH; Patel J
J Clin Oncol; 2007 May; 25(15):2140; author reply 2141. PubMed ID: 17513824
[No Abstract] [Full Text] [Related]
2. Sparing of previously irradiated skin from erlotinib-induced acneiform rash.
Yalçin S; Dizdar O; Yalçin B; Gököz O
J Am Acad Dermatol; 2008 Jan; 58(1):178-9. PubMed ID: 18158935
[No Abstract] [Full Text] [Related]
3. Newly recognized ocular side effects of erlotinib.
Methvin AB; Gausas RE
Ophthalmic Plast Reconstr Surg; 2007; 23(1):63-5. PubMed ID: 17237697
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting.
Gridelli C; Maione P; Amoroso D; Baldari M; Bearz A; Bettoli V; Cammilluzzi E; Crinò L; De Marinis F; Di Pietro FA; Grossi F; Innocenzi D; Micali G; Piantedosi FV; Scartozzi M
Crit Rev Oncol Hematol; 2008 May; 66(2):155-62. PubMed ID: 18083041
[TBL] [Abstract][Full Text] [Related]
5. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
[TBL] [Abstract][Full Text] [Related]
6. Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer.
Bidoli P; Cortinovis DL; Colombo I; Crippa A; Cicchiello F; Villa F; Cazzaniga ME; Altomare G
J Thorac Oncol; 2010 Oct; 5(10):1662-3. PubMed ID: 20871265
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management.
Tsimboukis S; Merikas I; Karapanagiotou EM; Saif MW; Syrigos KN
Clin Lung Cancer; 2009 Mar; 10(2):106-11. PubMed ID: 19362953
[TBL] [Abstract][Full Text] [Related]
8. The Koebner-phenomenon in epidermal growth factor receptor inhibitor-induced cutaneous adverse effects.
Gerber PA; Enderlein E; Homey B
J Clin Oncol; 2008 Jun; 26(16):2790-2. PubMed ID: 18509193
[No Abstract] [Full Text] [Related]
9. Erlotinib or gefitinib for non-small-cell lung cancer.
Yusuf SW; Kim P; Durand JB
N Engl J Med; 2011 Jun; 364(24):2367; author reply 2368. PubMed ID: 21675910
[No Abstract] [Full Text] [Related]
10. A case of radiation recall pneumonitis induced by erlotinib, which can be related to high plasma concentration.
Togashi Y; Masago K; Mishima M; Fukudo M; Inui K
J Thorac Oncol; 2010 Jun; 5(6):924-5. PubMed ID: 20502274
[No Abstract] [Full Text] [Related]
11. Palmar bullous blistering induced by erlotinib.
Berg A; Brustugun OT; Lund-Iversen M; Helland Å
J Thorac Oncol; 2011 May; 6(5):954. PubMed ID: 21623268
[No Abstract] [Full Text] [Related]
12. [Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)].
Tang CH; Liu XQ; Gao HJ; Li JJ; Guo WF; Li XY; Wang WX; Liu B; Qu LL; Wang WW
Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):143-7. PubMed ID: 20403247
[TBL] [Abstract][Full Text] [Related]
13. Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects.
Gerber PA; Enderlein E; Homey B; Muller A; Boelke E; Budach W
J Clin Oncol; 2007 Oct; 25(29):4697-8; author reply 4698-9. PubMed ID: 17925571
[No Abstract] [Full Text] [Related]
14. Epidermal growth factor receptor tyrosine kinase inhibitors and depression.
Pirl WF; Solis J; Greer J; Sequist L; Temel JS; Lynch TJ
J Clin Oncol; 2009 Aug; 27(23):e49-50; author reply e51. PubMed ID: 19597022
[No Abstract] [Full Text] [Related]
15. Erlotinib-induced rash spares previously irradiated skin.
Lips IM; Koster ME; Houwing RH; Vonk EJ
Strahlenther Onkol; 2011 Aug; 187(8):499-501. PubMed ID: 21789741
[TBL] [Abstract][Full Text] [Related]
16. Improving the assessment of erlotinib-induced rashes: a key to early detection and effective management.
Chon SY; Riddel C
J Support Oncol; 2009; 7(6):218-9. PubMed ID: 20380329
[No Abstract] [Full Text] [Related]
17. Folliculitis-perifolliculitis related to erlotinib therapy spares previously irradiated skin.
Acharya J; Lyon C; Bottomley DM
J Am Acad Dermatol; 2009 Jan; 60(1):154-7. PubMed ID: 19103369
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib-induced generalized eczema craquelé and follicular rash sparing the previous radiation field.
Chiu HY; Cheng YP; Jee SH; Tsai TF
Clin Exp Dermatol; 2012 Dec; 37(8):922-4. PubMed ID: 22731795
[No Abstract] [Full Text] [Related]
19. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
[TBL] [Abstract][Full Text] [Related]
20. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
Chen Q; Quan Q; Ding L; Hong X; Zhou N; Liang Y; Wu H
Oncotarget; 2015 Sep; 6(28):24904-11. PubMed ID: 26172562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
